Non-Small-Cell Lung Carcinoma in Women: A Retrospective Cohort Study in Indonesia
International Agency for Research on Cancer. Lung cancer: estimated incidence, mortality, and prevalence worldwide in 2012. Available at http://globocan.iarc.fr/old/FactSheets/cancers/lung-new.asp.
American Cancer Society. Key statistics for lung cancer. Available at https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/key-statistics.html.
Jemal A, Ward E, Thun MJ. Contemporary lung cancer trends among US women. Cancer Epidemiol Biomarkers Prev. 2005;14:582-5.
American Cancer Society. Cancer Facts and Figures 2017. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2017.html.
Patel JD, Bach PB, Kris MG. Lung cancer in US women: a contemporary epidemic. JAMA. 2004;291:1763-8.
Kligerman S, White C. Epidemiology of lung cancer in women: risk factors, survival, and screening. AJR. 2011;196:287-95.
Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival – Population-based study of 20,561 cases. Ann Oncol. 2002;13:1087-93.
Badar F, Meerza F, Khokhar RA, et al. Characteristics of lung cancer patients--the Shaukat Khanum Memorial experience. Asian Pac J Cancer Prev. 2006;7:245-8.
Katcoff H, Wenzlaff AS, Schwartz AG. Survival in women with NSCLC: the role of reproductive history and hormone use. J Thorac Oncol. 2014;9:355-61.
Wang P, Zou J, Wu J, et al. Clinical profiles and trend analysis of newly diagnosed lung cancer in a tertiary care hospital of East China during 2011-2015. J Thorac Dis. 2017;9:1973-9.
Remon J, Isla D, Garrido P, et al. Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database. Clin Transl Oncol. 2017 (in press).
Jenks S. Is lung cancer incidence increasing in never smokers? J Natl Cancer Inst. 2016;108:3-4.
Deng F, Li M, Shan W-L, et al. Correlation between epidermal growth factor receptor mutations and the expression of estrogen receptor-b in advanced non-small cell lung cancer. Oncol Lett. 2017;13:2359-65.
Sobue T, Yamamoto S, Hara M, Sasazuki S, Sasaki S, Tsugane S. Cigarette smoking and subsequent risk of lung cancer by histologic type in middle-aged Japanese men and women: the JPHC study. Int J Cancer. 2002;99:245-51.
Toh C-K, Wong E-H, Lim W-T, et al. The impact of smoking status on the behavior and survival outcome of patients with advanced non-small cell lung cancer: A retrospective analysis. Chest. 2004;126:1750-6.
Yu Y, Liu H, Zheng S, et al. Gender susceptibility for cigarette smoking-attributable lung cancer: a systematic review and meta-analysis. Lung Cancer. 2014;85:351-60.
Bain C, Feskanich D, Speizer FE, et al. Lung cancer rates in men and women with comparable histories of smoking. J Natl Cancer Inst. 2004;96:826-34.
Powell HA, Iyen-Omofoman B, Hubbard RB, Baldwin DR, Tata LJ. The association between smoking quantity and lung cancer in men and women. Chest. 2013;143:123-9.
Thomas L, Doyle A, Edelman MJ. Lung cancer in women: emerging differences in epidemiology, biology and therapy. Chest. 2005;128:370-81.
Wakalee HA, Chang ET, Gomez SL, et al. Lung cancer incidence in never smokers. J Clin Oncol. 2007;25:472-8.
Chakraborty S, Ganti AK, Marr A, Batra SK. Lung cancer in women: role of estrogen. Expert Rev Respir Med. 2010;4:509-18.
Siegfried JM, Hershberger PA, Stabile LP. Estrogen receptor signaling in lung cancer. Semin Oncol. 2009; 36:524-31.
Stabile LP, Davis G, Gubish CT, et al. Human non-small-cell lung tumours and cells derived from normal lung express both estrogen receptor a and b and show biological responses to estrogen. Cancer Res. 2002;62:2141-50.
Stabile LP, Dacic S, Land SR, et al. Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome. Clin Cancer Res. 2010;17:154-64.
Kazmi N, Márquez-Garbán DC, Aivazyan L, Garon EB, Goodglick L, Pietras RJ. The role of estrogen, progesterone and aromatase in human non-small-cell lung cancer. Lung Cancer Manag. 2012; 1:259-72.
Mah V, Seligson DB, Li A, et al. Aromatase expression predicts survival in women with early-stage non-small cell lung cancer. Cancer Res. 2007; 67:10484-90.
Chlebowski RT, Schwartz AG, Anderson GL, et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women’s Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet. 2009;374:1243-51.
Slatore CG, Chien JW, Au DH, et al. Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study. J Clin Oncol. 2010;28:1540-6.
Moore R, Doherty D, Chamberlain R, Khuri F. Sex differences in survival in non-small cell lung cancer patients 1974-1998. Acta Oncol. 2004;43:57-64.
Oton AB, Belani C, Owonikoko T, et al. Comparison of survival for non-small cell lung cancer between premenopausal and postmenopausal women: an analysis of the National Surveillance, Epidemiology and End Results (SEER) Database. J Clin Oncol (Meeting Abstr) 2006;24:7038.
Moore KA. Menopausal effects on presentation, treatment, and survival of women with non-small cell lung cancer. Ann Thorac Surg. 2003;76(6):1789–95.
Viñolas N, Garrido P, Isla D, et al. Lung cancer in never-smoking women: A sub-analysis of the Spanish Female-Specific Database WORLD07. Cancer Invest. 2017;35(5):358–65.
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu D, Saijo N. Phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 2008;19.viii1-viii4.
- There are currently no refbacks.